Nomination Committee’s proposal to the Board of Directors for IRLAB Therapeutics’ Annual General Meeting 2026

Gothenburg, Sweden, April 17, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the Nomination Committee proposes the election of Jan‐Fredrik Backman as new Vice Chairperson and James Gamgort as new Board member at the Annual General Meeting in 2026. The Nomination Committee further proposes the re‐election of Chairperson Carola Lemne and Board members Gunnar Olsson, Rein Piir and Veronica Wallin. Christer Nordstedt has declined re‐election.

IRLAB to present at Redeye Healthcare Day 2026

IRLAB to present clinical and preclinical data at the AD/PD™ 2026 – 20th International Conference on Alzheimer’s & Parkinson’s Diseases